Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells

Journal of Experimental Medicine

Volumn 185, Issue 7, 1997, Pages 1337-1347

  Darley, Richard L ^a   Hoy, Terence G ^a   Baines, Paul ^a   Padua, Rose Ann ^a   Burnett, Alan K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DYSPLASIA; ERYTHROID CELL; ERYTHROPOIESIS; EXPRESSION VECTOR; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE N RAS; PRIORITY JOURNAL;

ACUTE DISEASE; ANTIGENS, CD34; APOPTOSIS; CELL DIFFERENTIATION; ERYTHROID PROGENITOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; GENES, RAS; GENES, REPORTER; HUMANS; LEUKEMIA, MYELOID; MUTATION; MYELODYSPLASTIC SYNDROMES; PRELEUKEMIA;

EID: 0030903188     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.7.1337     Document Type: Article

References (65)

1. Barbacid, M. 1987. Ras genes. Annu. Rev. Biochem. 56:779-827.
2. Satoh, T., M. Nakafuku, A. Miyajima, and Y. Kaziro. 1991. Involvement of ras p21 protein in signal-transduction pathways from interleukin-2, interleukin-3, and granulocyte macrophage colony-stimulating factor, but not from interleukin-4. Proc. Natl. Acad. Sci. USA. 88:3314-3318.
3. Torti, M., K.B. Marti, D. Altschuler, K. Yamamoto, and E.G. Lapetina. 1992. Erythropoietin induces p21(ras) activation and p120GAP tyrosine phosphorylation in human erythroleukemia-cells. J. Biol. Chem. 267:8293-8298.
4. Marshall, M.S. 1995. Ras target proteins in eukaryotic cells. FASEB J. 9:1311-1318.
5. Kiaris, H., and D.A. Spandidos. 1995. Mutations of ras genes in human tumours. Int. J. Oncol. 7:413-121.
6. Bartram, C.R. 1992. Molecular genetic aspects of myelodysplastic syndromes. Hematol. Oncol. Clin. N. Am. 6:557-570.
7. Parker, J., and G.J. Mufti. 1996. Ras and myelodysplasia: lessons from the last decade. Semin. Hematol. 33:206-224.
8. Goga, A., J. McLaughlin, D.E.H. Afar, D.C. Saffran, and O.N. Witte. 1995. Alternative signals to RAS for haematopoietic transformation by BCR-ABL oncogene. Cell. 82: 981-988.
9. Kaira, R., D.C. Paderanga, K. Olson, and K.M. Shannon. 1995. Genetic analysis is consistant with the hypothesis that NF-1 limits myeloid cell growth through p21ras. Blood. 84: 3435-3439.
10. Shen, W.P.V., T.H. Aldrich, G. Venta-Perez, B.R. Franza, and M.E. Furth. 1987. Expression of normal and mutant ras proteins in human acute leukaemia. Oncogene. 1:157-165.
11. Gallagher, A.G., R.A. Padua, A. Alsabah, A.K. Burnett, and R.L. Darley. 1995. Overexpression of p21RAS but not p120GAP is a common feature of myelodysplasia. Leukemia (Basingstoke). 9:1833-1840.
12. May, S.J., S.A. Smith, A. Jacobs, A. Williams, and R. Baileywood. 1985. The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification. Br. J. Haematol. 59:311-319.
13. Ruutu, T., S. Partenen, R. Lintula, L. Teerenhovi, and S. Knuutila. 1984. Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Scand. J. Haematol. 32:395-402.
14. Chui, D.H.K. and B.J. Clarke. 1982. Abnormal erythroid progenitor cells in human preleukemia. Blood. 60:362-367.
15. Janssen, J.W.G., M. Buschle, M. Layton, H.G. Drexler, J. Lyons, H. Vandenberghe, H. Heimpel, B. Kubanek, E. Kleihauer, G.J. Mufti, and C.R. Bartram. 1989. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem-cell origin. Blood. 73:248-254.
16. Gallagher, A.G., R.L. Darley, and R.A. Padua. 1997. The molecular basis of myelodysplastic syndrome. Haematologica. In press.
17. Kiem, H.P., B. Darovsky, C. Vonkalle, S. Goehle, D. Stewart, T. Graham, R. Hackman, F.R. Appelbaum, H.J. Deeg, A.D. Miller et al. 1994. Retrovirus-mediated gene transduction into canine peripheral-blood repopulating cells. Blood. 83:1467-1473.
18. Fibach, E., and E.A. Rachmilewitz. 1993. The 2-step liquid culture: a novel procedure for studying maturation of human normal and pathological erythroid precursors. Stem Cells. 11: 36-41.
19. Baines, P., L. Truran, R. Baileywood, T. Hoy, H. Lake, C.H. Poynton, and A. Burnett. 1994. Hematopoietic colony-forming cells from peripheral-blood stem-cell harvests: cytokine requirements and lineage potential. Br. J. Haematol. 88: 472-480.
20. Nolan, G.P., S. Fiering, J.F. Nicolas, and L.A. Herzenberg. 1988. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-d-galactosidase activity after transduction of Escherichia coli lacZ. Proc. Natl. Acad. Sci. USA. 85:2603-2607.
21. Watson, J.V., S.H. Chambers, and P.J. Smith. 1987. A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry. 8:1-8.
22. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 7.43-7.50.
23. Raza, A., S. Gezer, S. Mundle, X.Z. Gao, S. Alvi, R. Borok, S. Rifkin, A. Iftikhar, V. Shetty, A. Parcharidou et al. 1995. Apoptosis in bone-marrow biopsy samples involving stromal and hematopoietic-cells in 50 patients with myelodysplastic syndromes. Blood. 86:268-276.
24. Di Stefano, M., A. Cortelezzi, B. Sarina, S. Giannini, M. Pomati, I. Silvestris, C. Cattaneo, R. Calori, G.L. Gornati, and A.T. Maiolo. 1996. Evidence of apoptosis in myelodysplastic syndromes (MDS): involvement of the BCL2 protooncogene. Br. J. Haematol. 93:587. (Abstr.)
25. Kouraklis, A., P. Tsoplou, A. Symeonidis, V. Orphanos, and N. Zoumbos. 1996. The clinical-significance or apoptosis in the marrow of patients with primary myelodysplastic syndromes (MDS). Br. J. Haematol. 93:263. (Abstr.)
26. Kelley, L.L., W.F. Green, G.G. Hicks, M.C. Bondurant, M.J. Koury, and H.E. Ruley. 1994. Apoptosis in erythroid progenitors deprived of erythropoietin occurs during G(1)-phase and S-phase of the cell-cycle without growth arrest or stabilization of wild-type p53. Mol. Cell Biol. 14:4183-4192.
27. Martin, S.J., C.P.M. Reutelingsperger, A.J. Mcgahon, J.A. Rader, R.C.A.A. Vanschie, D.M. Laface, and D.R. Green. 1995. Early redistribution of plasma-membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of BCL-2 and ABL. J. Exp. Med. 182:1545-1556.
28. Homburg, C.H.E., M. Dehaas, A.E.G.K. Vondemborne, A.J. Verhoeven, C.P.M. Reutelingsperger, and D. Roos. 1995. Human neutrophils lose their surface Fc-gamma-RIII and acquire annexin-V binding-sites during apoptosis in vitro. Blood. 85:532-540.
29. Vermes, I., C. Haanen, H. Steffensnakken, and C. Reutelingsperger. 1995. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein-labeled annexin-V. J. Immunol. Methods. 184:39-51.
30. Koopman, G., C.P. Reutelingsperger, G.A. Kuijten, R.M. Keehnen, S.T. Pals, and M.H. van Oers. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1415-1420.
31. Vanengeland, M., F.C.S. Ramaekers, B. Schutte, and C.P.M. Reutelingsperger. 1996. A novel assay to measure loss of plasma-membrane asymmetry during apoptosis of adherent cells in culture. Cytometry. 24:131-139.
32. Kansas, G.S., M.J. Muirhead, and M.O. Dailey. 1990. Expression of the CD11/CD18, leukocyte adhesion molecule-1, and CD44 adhesion molecules during normal myeloid and erythroid-differentiation in humans. Blood. 76:2483-2492.
33. Loken, M.R., V.O. Shah, K.L. Dattilio, and C.I. Civin. 1987. Flow cytometric analysis of human-bone marrow. I. Normal erythroid development. Blood. 69:255-263.
34. Okumura, N., K. Tsuji, and T. Nakahata. 1992. Changes in cell-surface antigen expressions during proliferation and differentiation of human erythroid progenitors. Blood. 80:642-650.
35. Shintani, N., Y. Kohgo, J. Kato, H. Kondo, K. Fujikawa, E. Miyazaki, and Y. Niitsu. 1994. Expression and extracellular release of transferrin receptors during peripheral erythroid progenitor-cell differentiation in liquid culture. Blood. 83:1209-1215.
36. Andrejauskas, E., and C. Moroni. 1989. Reversible abrogation of IL-3 dependence by an inducible H-RAS oncogene. EMBO (Eur. Mol. Biol. Organ.) J. 8:2575-2581.
37. Maher, J., D. Baker, N. Dibb, and I. Roberts. 1996. Mutant ras promotes haemopoietic cell proliferation or differentiation in a cell-specific manner. Leukemia (Basingstoke). 10:83-90.
38. Jones, B.M., A.D. White, D.J. Culligan, and A. Jacobs. 1992. Cell-cycle progression rates and sister chromatid exchange frequencies in the bone marrow of patients with myelodysplastic syndrome and acute myeloid leukemia. Cancer Genet. Cytogenet. 62:66-69.
39. Montecucco, C., A. Riccardi, E. Traversi, P. Giordano, G. Mazzini, and E. Ascari. 1983. Proliferative activity of bone marrow cells in primary dymyelopoietic (preleukaemic) syndromes. Cancer (Phila.). 52:1190-1195.
40. Jensen, I.M., M. Hokland, and P. Hokland. 1993. A quantitative-evaluation of erythropoiesis in myelodysplastic syndromes using multiparameter flow-cytometry. Leuk. Res. 17: 839-846.
41. + cells. Blood. 85:194-202.
42. Backx, B., L. Broeders, I. Touw, and B. Lowenberg. 1993. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia (Baltimore). 7:75-79.
43. Papayannopoulou, T., and J. Abkowitz. 1991. Biology of erythropoiesis, erythroid differentiation, and maturation. In Haematology, Basic Principles and Practice. R. Hoffman, editor. Churchill-Livingstone, Inc., New York. 252-263.
44. Ponka, P., and H.M. Schulman. 1993. Regulation of hemebiosynthesis: distinct regulatory features in erythroid-cells. Stem Cells. 11:24-35.
45. Nijhof, W., G. Dehaan, J. Pietens, and B. Dontje. 1995. Mechanistic options of erythropoietin-stimulated erythropoiesis. Exp. Hematol. 23:369-375.
46. Wu, H., X. Liu, R. Jaenisch, and H.F. Lodish. 1995. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 83:59-67.
47. Koury, M.J., and M.C. Bondurant. 1990. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science (Wash. DC). 248:378-381.
48. Muta, K., S.B. Krantz, M.C. Bondurant, and C.H. Dai. 1995. Stem-cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation. Blood. 86:572-580.
49. Wu, H., U. Klingmuller, P. Besmer, and H.F. Lodish. 1995. Interaction of the erythropoietin and stem-cell-factor receptors. Nature (Lond.). 377:242-246.
50. Backx, B., L. Broeders, L.H. Hoefsloot, B. Wognum, and B. Lowenberg. 1996. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit-ligand. Leukemia (Baltimore). 10:466-472.
51. Miura, Y., O. Miura, J.N. Ihle, and N. Aoki. 1994. Activation of the mitogen-activated protein-kinase pathway by the erydiropoietin receptor. J. Biol. Chem. 269:29962-29969.
52. Delachapelle, A., A.L. Traskelin, and E. Juvonen. 1993. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc. Natl. Acad. Sci. USA. 90:4495-4499.
53. Klingmuller, U., U. Lorenz, L.C. Cantley, B.G. Neel, and H.F. Lodish. 1995. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 80:729-738.
54. Krautwald, S., D. Buscher, V. Kummer, S. Buder, and M. Baccarini. 1996. Involvement of the protein-tyrosine-phosphatase SHP-1 in ras-mediated activation of the mitogen-activated protein-kinase pathway. Mol. Cell Biol. 16:5955-5963.
55. Tsui, H.W., K.A. Siminovitch, L. Desouza, and F.W.L. Tsui. 1993. Moth-eaten and viable moth-eaten mice have mutations in the hematopoietic-cell phosphatase gene. Nat. Genet. 4:124-129.
56. van Zant, G., and L. Shultz. 1989. Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev). Exp. Haematol. (Charlottesv.). 17:81-87.
57. Dybedal, I., and S.E.W. Jacobsen. 1995. Transforming growth-factor-beta (TGF-beta), a potent inhibitor of erythropoiesis-neutralizing TGF-beta antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activity. Blood. 86:949-957.
58. Rusten, L.S., and S.E.W. Jacobsen. 1995. Tumor-necrosis-factor (TNF)-alpha directly inhibits human erythropoiesis invitro: role of p55 and p75 TNF receptors. Blood. 85:989-996.
59. Morishita, K., E. Parganas, C.L. Willman, M.H. Whittaker, H. Drabkin, J. Oval, R. Taetle, M.B. Valentine, and J.N. Ihle. 1992. Activation of Evi1 gene-expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band-3q26. Proc. Natl. Acad. Sci. USA. 89:3937-3941.
60. Fichelson, S., F. Dreyfus, R. Berger, J. Melle, C. Bastard, J.M. Miclea, and S. Gisselbrecht. 1992. Evi-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia (Basingstoke). 6:93-99.
61. Bellomo, M.J., V. Parlier, D. Muhlematter, J.P. Grob, and P. Beris. 1992. 3 new cases of chromosome-3 rearrangement in band-q21 and band-q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26-syndrome. Cancer Genet. Cytogenet. 59:138-160.
62. Kreider, B.L., S.H. Orkin, and J.N. Ihle. 1993. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc. Natl. Acad. Sci. USA. 90:6454-6458.
63. Hibi, S., J. Lohler, J. Friel, C. Stocking, and W. Ostertag. 1993. Induction of monocytic differentiation and tumorigenicity by v-Ha-ras in differentiation-arrested haematopoietic cells. Blood. 81:1841-1848.
64. Jin, D.I., S.B. Jameson, M.A. Reddy, O. Schenkman, and M.C. Ostrowski. 1995. Alterations in differentiation and behavior of monocytic phagocytes in transgenic mice that express dominant suppressors of ras signaling. Mol. Cell Biol. 15: 693-703.
65. Skorski, T., C. Szczylik, M.Z. Ratajczak, L. Malaguarnera, A.M. Gewirtz, and B. Calabretta. 1992. Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J. Exp. Med. 175:743-750.